Surprising lack of liposome-induced complement activation by artificial 1,3-diamidophospholipids in vitro

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 3, 2016, Pages 845-849

  Bugna, Simon ^a   Buscema, Marzia ^a   Matviykiv, Sofiya ^a   Urbanics, Rudolf ^b   Weinberger, Andreas ^c   Meszaros, Tamas ^b   Szebeni, Janos ^b   Zumbuehl, Andreas ^c   Saxer, Till ^d   Müller, Bert ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY OF FRIBOURG   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

CARPA; Pad PC Pad; Physical trigger; Pig study; Shear sensitive nano container

Indexed keywords

BLOOD VESSELS; CHEMICAL ACTIVATION; CLINICAL RESEARCH; CONTAINERS; CONTROLLED DRUG DELIVERY; LIPOSOMES; MAMMALS; PHOSPHOLIPIDS; SHEAR STRESS; TARGETED DRUG DELIVERY;

CARDIO-VASCULAR DISEASE; CARPA; COMPLEMENT ACTIVATIONS; DRUG CARRIER SYSTEMS; HEMODYNAMIC CHANGES; PAD-PC-PAD; PHYSICAL TRIGGER; PIG STUDY;

DISEASES;

1,3 DIAMIDOPHOSPHOLIPID; DRUG CARRIER; LIPOSOME; PHOSPHOLIPID; UNCLASSIFIED DRUG; 1,3-DIPALMITAMIDOPROPAN-2-YL 2-(TRIMETHYLAMMONIO)ETHYL PHOSPHATE; COMPLEMENT;

ARTICLE; COMPLEMENT ACTIVATION; ELECTROCARDIOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART RATE; HUMAN; IN VITRO STUDY; NONHUMAN; ANIMAL; BLOOD; CHEMISTRY; DRUG EFFECTS; FEMALE; HEMODYNAMICS; IMMUNOLOGY; PIG;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; FEMALE; HEMODYNAMICS; HUMANS; LIPOSOMES; PHOSPHOLIPIDS; SWINE;

EID: 84958214298     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.12.364     Document Type: Article

References (17)

1. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Borden W.B., et al. Heart disease and stroke statistics-2013 update. A report from the American Heart Association. Circulation 2013, 127:e6-e245.
2. Crielaard B.J., Lammers T., Schiffelers R.M., Storm G. Drug targeting systems for inflammatory disease: one for all, all for one. J Control Release 2012, 161:225-234.
3. Ruiz-Esparza G.U., Flores-Arredondo J.H., Segura-Ibarra V., Torre-Amione G., Ferrari M., Blanco E., et al. The physiology of cardiovascular disease and innovative liposomal platforms for therapy. Int J Nanomedicine 2013, 8:629-640.
4. Saxer T., Zumbuehl A., Müller B. The use of shear stress for targeted drug delivery. Cardiovasc Res 2013, 99:328-333.
5. Holme M.N., Fedotenko I.A., Abegg D., Althaus J., Babel L., Favarger F., et al. Shear-stress sensitive lenticular vesicles for targeted drug delivery. Nat Nanotechnol 2012, 7:536-543.
6. Nath P., Basher A., Harada M., Sarkar S., Selim S., Maude R.J., et al. Immediate hypersensitivity reaction following liposomal amphotericin-B (AmBisome) infusion. Trop Dr 2014, 44:241-242.
7. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 2005, 216:106-121.
8. Chanan-Khan A., Szebeni J., Savay S., Liebes L., Rafique N.M., Alving C.R., et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions. Ann Oncol 2003, 14:1430-1437.
9. Lyass O., Uziely B., Ben-Yosef R., Tzemach D., Heshing N.I., Lotem M., et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000, 89:1037-1047.
10. Northfelt D.W., Dezube B.J., Thommes J.A., Miller B.J., Fischl M.A., Friedman-Kien A., et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998, 16:2445-2451.
11. Barratt G., Bretagne S. Optimizing efficacy of Amphotericin B through nanomodification. Int J Nanomedicine 2007, 2:301-313.
12. Olson F., Hunt C.A., Szoka F.C., Vail W.J., Papahadjopoulos D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta Biomembr 1979, 557:9-23.
13. Szebeni J., Bedocs P., Urbanics R., Bünger R., Rosivall L., Tóth M., et al. Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model. J Control Release 2012, 160:382-387.
14. Müller-Eberhard H.J. The membrane attack complex 1984.
15. Cooper C.A., Moraes L.E., Murray J.D., Owens S.D. Hematologic and biochemical reference intervals for specific pathogen free 6-week-old Hampshire-Yorkshire crossbred pigs. J Anim Sci Biotechnol 2014, 5:5.
16. Clinical Biochemistry of Domestic Animals 2008, Academic Press, San Diego. 6th ed. J.J. Kaneko, J.W. Harvey, M.L. Bruss (Eds.).
17. Szebeni J., Fontana J.L., Wassef N.M., Mongan P.D., Morse D.S., Dobbins D.E., et al. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes: role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 1999, 99:2302-2309.